Published in Oncotarget on May 10, 2016
Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol (2016) 0.83
Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene. Genes (Basel) (2016) 0.79
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications. Genes (Basel) (2016) 0.79
The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Oncotarget (2017) 0.75
Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infect Agent Cancer (2017) 0.75
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Hepatocellular carcinoma. Lancet (2012) 18.09
Cancer statistics in China, 2015. CA Cancer J Clin (2016) 12.92
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer (1997) 5.80
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol (2014) 3.68
Frequency of TERT promoter mutations in human cancers. Nat Commun (2013) 3.13
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med (2014) 2.24
High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer (2004) 1.95
World Health Organization classification of tumors. Cancer (2000) 1.77
Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA. Nat Struct Mol Biol (2010) 1.72
The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene (2013) 1.66
TERT promoter mutations in cancer development. Curr Opin Genet Dev (2013) 1.58
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab (2014) 1.52
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol (2014) 1.49
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem (2010) 1.32
DNA extraction from paraffin embedded material for genetic and epigenetic analyses. J Vis Exp (2011) 1.27
Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch (2014) 1.09
Telomerase as a "stemness" enzyme. Sci China Life Sci (2014) 1.02
Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget (2015) 1.00
TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer (2014) 0.99
TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget (2014) 0.94
TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Int J Surg (2014) 0.93
Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol (2005) 0.92
Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch (2014) 0.90
The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer. Oncotarget (2015) 0.89
Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition). Chin Clin Oncol (2012) 0.87
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol (2015) 0.86
Deciphering gene expression program of MAP3K1 in mouse eyelid morphogenesis. Dev Biol (2012) 0.85
Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol (2015) 0.84
Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. Oncotarget (2016) 0.83
TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma. J Hepatol (2014) 0.83
Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. Mod Pathol (2014) 0.80
Nuclear translocation of telomerase reverse transcriptase: a critical process in chemical induced hepatocellular carcinogenesis. Neoplasma (2010) 0.80
Telomerase reverse transcriptase (TERT) expression in canine mammary tissues: a specific marker for malignancy? Anticancer Res (2009) 0.79
Increased p16 and p53 protein expression predicts poor prognosis in mucosal melanoma. Oncotarget (2017) 0.75
Increased p16 and p53 protein expression predicts poor prognosis in mucosal melanoma. Oncotarget (2017) 0.75